NOVORAPID PENFILL INJECTION 100 uml

Land: Singapore

Språk: engelsk

Kilde: HSA (Health Sciences Authority)

Aktiv ingrediens:

Insulin aspart

Tilgjengelig fra:

NOVO NORDISK PHARMA (SINGAPORE) PTE LTD

ATC-kode:

A10AB05

Dosering :

100 u/ml

Legemiddelform:

INJECTION

Sammensetning:

Insulin aspart 100 u/ml

Administreringsrute:

INTRAVENOUS, SUBCUTANEOUS

Resept typen:

Prescription Only

Produsert av:

Novo Nordisk A/S

Autorisasjon status:

ACTIVE

Autorisasjon dato:

2000-09-12

Informasjon til brukeren

1
NOVORAPID
®
 PENFILL
®

100 U/ml solution for injection in cartridge. 

QUALITATIVE AND QUANTITATIVE COMPOSITION  
1 ml of the solution contains 100 U of insulin aspart
 (equivalent to 3.5 mg). 
1 cartridge contains 3 ml equivalent to 300 U. 

Insulin aspart is produced by recombinant DNA technology
in _Saccharomyces cerevisiae._  

PHARMACEUTICAL FORM 
Clear, colourless, aqueous solution for injection in cartridge.
Penfill
®
. 

THERAPEUTIC INDICATIONS 
Treatment of diabetes mellitus in adults, adolescents and children
aged 2 years and above.  

POSOLOGY 
NovoRapid
®
 is a rapid-acting insulin analogue. NovoRapid
®
 dosage is individual and determined in 
accordance with the needs of the patient. It should normally be
used in combination with intermediate-
acting or long-acting insulin given at least once a day. Blood
glucose monitoring and insulin dose 
adjustment are recommended to achieve optimal glycaemic control. 

The individual insulin requirement in adults and children is
usually between 0.5 and 1.0 U/kg/day. In a 
basal-bolus treatment regimen, 50 - 70% of this requirement may be
provided by NovoRapid
®
 and the 
remainder by intermediate-acting or long-acting insulin.
Adjustment of dosage may be necessary if 
patients undertake increased physical activity, change their usual
diet or during concomitant illness. 

NovoRapid
®
 has a faster onset and a shorter duration of action than soluble
human insulin. 

Due to the faster onset of action, NovoRapid
®
 should generally be given immediately before a meal. 
When necessary NovoRapid
®
 can be given soon after a meal. 

Due to the shorter duration, NovoRapid
®
 has a lower risk of causing nocturnal hypoglycaemic 
episodes. 

SPECIAL POPULATIONS 
As with all insulin products, in elderly patients and patients with
renal or hepatic impairment, glucose 
monitoring should be intensified and the insulin aspart dosage
adjusted on an i

Preparatomtale

1
NOVORAPID
®
Penfill
®
100 U/ml solution for injection in cartridge.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml of the solution contains 100 U of insulin aspart* (equivalent to
3.5 mg).
1 cartridge contains 3 ml equivalent to 300 U.
*Insulin aspart is produced by recombinant DNA technology in
_Saccharomyces cerevisiae._
PHARMACEUTICAL FORM
Clear, colourless, aqueous solution for injection in cartridge.
Penfill
®
.
THERAPEUTIC INDICATIONS
Treatment of diabetes mellitus in adults, adolescents and children
aged 2 years and above.
POSOLOGY
NovoRapid
®
is a rapid-acting insulin analogue. NovoRapid
®
dosage is individual and determined in
accordance with the needs of the patient. It should normally be used
in combination with intermediate-
acting or long-acting insulin given at least once a day. Blood glucose
monitoring and insulin dose
adjustment are recommended to achieve optimal glycaemic control.
The individual insulin requirement in adults and children is usually
between 0.5 and 1.0 U/kg/day. In a
basal-bolus treatment regimen, 50–70% of this requirement may be
provided by NovoRapid
®
and the
remainder by intermediate-acting or long-acting insulin. Adjustment of
dosage may be necessary if
patients undertake increased physical activity, change their usual
diet or during concomitant illness.
NovoRapid
®
has a faster onset and a shorter duration of action than soluble human
insulin.
Due to the faster onset of action, NovoRapid
®
should generally be given immediately before a meal.
When necessary NovoRapid
®
can be given soon after a meal.
Due to the shorter duration, NovoRapid
®
has a lower risk of causing nocturnal hypoglycaemic
episodes.
SPECIAL POPULATIONS
As with all insulin products, in elderly patients and patients with
renal or hepatic impairment, glucose
monitoring should be intensified and the insulin aspart dosage
adjusted on an individual basis.
PAEDIATRIC POPULATION
NovoRapid
®
can be used in children aged 2 year and above in preference to soluble
human insulin
when a rapid onset of actio